GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NervGen Pharma Corp (TSXV:NGEN) » Definitions » Price-to-Owner-Earnings

NervGen Pharma (TSXV:NGEN) Price-to-Owner-Earnings : (As of May. 15, 2024)


View and export this data going back to 2019. Start your Free Trial

What is NervGen Pharma Price-to-Owner-Earnings?

As of today (2024-05-15), NervGen Pharma's share price is C$2.11. NervGen Pharma does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for NervGen Pharma's Price-to-Owner-Earnings or its related term are showing as below:


TSXV:NGEN's Price-to-Owner-Earnings is not ranked *
in the Biotechnology industry.
Industry Median: 34.09
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-05-15), NervGen Pharma's share price is C$2.11. NervGen Pharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was C$-0.38. Therefore, NervGen Pharma's PE Ratio for today is At Loss.

As of today (2024-05-15), NervGen Pharma's share price is C$2.11. NervGen Pharma's EPS without NRI for the trailing twelve months (TTM) ended in was C$-0.29. Therefore, NervGen Pharma's PE Ratio without NRI for today is At Loss.


NervGen Pharma Price-to-Owner-Earnings Historical Data

The historical data trend for NervGen Pharma's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NervGen Pharma Price-to-Owner-Earnings Chart

NervGen Pharma Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Owner-Earnings
Get a 7-Day Free Trial - - - - -

NervGen Pharma Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of NervGen Pharma's Price-to-Owner-Earnings

For the Biotechnology subindustry, NervGen Pharma's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NervGen Pharma's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NervGen Pharma's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where NervGen Pharma's Price-to-Owner-Earnings falls into.



NervGen Pharma Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

NervGen Pharma's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=2.11/-0.38
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


NervGen Pharma  (TSXV:NGEN) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


NervGen Pharma Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of NervGen Pharma's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


NervGen Pharma (TSXV:NGEN) Business Description

Traded in Other Exchanges
Address
2955 Virtual Way, Suite 480, Vancouver, BC, CAN, V5M 4X6
NervGen Pharma Corp is a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases. The company is developing drugs for the treatment of spinal cord injury, multiple sclerosis, and Alzheimer's disease. It operates in a single segment, which is the research and development of pharmaceutical drugs.
Executives
John Ruffolo Director

NervGen Pharma (TSXV:NGEN) Headlines

No Headlines